Tesamorelin

The published literature on Tesamorelin is unusually deep for a research peptide. A meta-analysis of five randomised controlled trials, published in Obesity Research & Clinical Practice in January, reported a significant reduction in visceral adipose tissue (mean difference −27.71 cm²), a reduction in trunk fat of 1.18 kg, and an increase in lean body mass of 1.42 kg, alongside raised IGF-1 — with no significant change in subcutaneous fat or BMI. A separate systematic review pooling four trials across 909 participants reached broadly the same conclusions.

Liver-focused work has drawn particular attention. A randomised placebo-controlled trial in HIV-associated NAFLD found that Tesamorelin reduced liver fat and prevented fibrosis progression over twelve months, and a follow-up analysis of paired liver biopsies from the same trial mapped the inflammatory and fibrotic gene-expression pathways that shifted alongside it. Cognitive endpoints have been examined too, in a Phase II trial in ageing HIV-positive adults (NCT02572323), where the between-group difference did not reach significance — a reminder that the GH–IGF-1 axis does not behave uniformly across every outcome studied.

Tesamorelin is studied in GHRH receptor pharmacology, pituitary growth-hormone release, downstream IGF-1 signalling and metabolic-endocrine models. Its enhanced stability compared with native GHRH makes it useful for studying sustained receptor activation and the consequences of altered hypothalamic-pituitary signalling.